Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of benzydamine hydrochloride + dichlorobenzyl alcohol lozenges for acute pharyngitis
2025-521764-35-01Phase 3Authorised
- Sponsor
- Medice
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibuprofen + levomenthol, benzydamine and 2,4-dichlorobenzyl alcohol in acute pharyngitis (3 arms), sponsored by Medice. Primary endpoint: Primary efficacy endpoint. Planned start Jan 2026; status: authorised.
02
Drugs
ibuprofen + levomentholbenzydamine2,4-dichlorobenzyl alcohol
03
Conditions
acute pharyngitis
Beyond the preview
Go deeper on 2025-521764-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521764-35-01.